LIVSANE Xylo PLUS Nasenspray
LIVSANE Xylo PLUS Nasenspray is a medicine authorised by Swissmedic under authorisation number 70276. The authorisation holder is Pharmapost AG. The medicinal product code is Synthetic medicines and the dispensing category is D: Supplied in pharmacies and drugstores after specialist advice, without a prescription. First authorisation was granted on 05 June 2025 and the authorisation is valid without a time limit. ATC code R01AB06 places the medicine in the group Nasal preparations.
| Authorisation number | 70276 |
|---|---|
| Name | LIVSANE Xylo PLUS Nasenspray |
| Full name | LIVSANE Xylo PLUS Nasenspray, Lösung |
| Authorisation holder | Pharmapost AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | D · No prescription, with advice |
| ATC code | R01AB06 |
| First authorisation | 05 June 2025 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | LIVSANE Xylo PLUS Nasenspray, Lösung | D | 05 June 2025 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 10 | ml | R01AB06 | 12.02.2. | D |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is LIVSANE Xylo PLUS Nasenspray authorised in Switzerland?
Yes. LIVSANE Xylo PLUS Nasenspray is authorised by Swissmedic under authorisation number 70276, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does LIVSANE Xylo PLUS Nasenspray have?
LIVSANE Xylo PLUS Nasenspray is in dispensing category D. Supplied in pharmacies and drugstores after specialist advice, without a prescription.
Who is the authorisation holder of LIVSANE Xylo PLUS Nasenspray?
The authorisation holder is Pharmapost AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.